{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:04:54Z","timestamp":1785168294915,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016016","name":"Gilead UK and Ireland Corporate Contributions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ajt.2025.09.012","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T18:36:10Z","timestamp":1758134170000},"page":"359-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and efficacy of tenofovir alafenamide in preventing hepatitis B virus recurrence after liver transplantation in patients with chronic kidney disease maintained on tenofovir disoproxil fumarate: Results from a phase 2 randomized trial"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4086-7955","authenticated-orcid":false,"given":"Edward J.","family":"Gane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7595-5905","authenticated-orcid":false,"given":"Rica","family":"Dagooc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Ray-Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vithika","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7509-1121","authenticated-orcid":false,"given":"Frida","family":"Abramov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis D.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-8173","authenticated-orcid":false,"given":"Catherine","family":"Frenette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu O.","family":"Osinusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7308-4880","authenticated-orcid":false,"given":"John F.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ajt.2025.09.012_bib1","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.cgh.2023.04.015","article-title":"The global burden of liver disease","volume":"21","author":"Younossi","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.ajt.2025.09.012_bib2","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.ajt.2025.09.012_bib5","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.cgh.2023.04.005","article-title":"Liver transplantation 2023: status report, current and future challenges","volume":"21","author":"Terrault","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ajt.2025.09.012_bib6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2018.06.010","article-title":"Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry","volume":"69","author":"Belli","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.ajt.2025.09.012_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.ajt.2025.09.012_bib8","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"9865","key":"10.1016\/j.ajt.2025.09.012_bib9","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ajt.2025.09.012_bib10","article-title":"Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"5","author":"Lim","year":"2023","journal-title":"JHEP Rep"},{"issue":"7","key":"10.1016\/j.ajt.2025.09.012_bib11","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/liv.14860","article-title":"Antiviral prophylaxis against hepatitis B recurrence after liver transplantation: current concepts","volume":"41","author":"Orfanidou","year":"2021","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.ajt.2025.09.012_bib12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cld.2021.06.009","article-title":"Use of hepatitis B virus\u2013positive organs in organ transplantation","volume":"25","author":"Khemichian","year":"2021","journal-title":"Clin Liver Dis"},{"issue":"9","key":"10.1016\/j.ajt.2025.09.012_bib13","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.dld.2018.03.032","article-title":"Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: a 5-year follow-up study after hepatitis B immunoglobulin withdrawal","volume":"50","author":"Manini","year":"2018","journal-title":"Dig Liver Dis"},{"issue":"25","key":"10.1016\/j.ajt.2025.09.012_bib14","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199312163292503","article-title":"Liver transplantation in European patients with the hepatitis B surface antigen","volume":"329","author":"Samuel","year":"1993","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajt.2025.09.012_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jlts.2000.8310","article-title":"Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B","volume":"6","author":"Angus","year":"2000","journal-title":"Liver Transpl"},{"issue":"3","key":"10.1016\/j.ajt.2025.09.012_bib16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/lt.23600","article-title":"Combination lamivudine plus adefovir without HBIG is safe and effective prophylaxis against HBV recurrence in HBsAg+ liver transplant candidates","volume":"19","author":"Gane","year":"2013","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.ajt.2025.09.012_bib17","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/hep.29191","article-title":"Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years","volume":"66","author":"Fung","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ajt.2025.09.012_bib18","article-title":"A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir","volume":"174","author":"Lumley","year":"2024","journal-title":"J Clin Virol"},{"issue":"2","key":"10.1016\/j.ajt.2025.09.012_bib19","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.04454-14","article-title":"Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.ajt.2025.09.012_bib20","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/ki.2010.318","article-title":"Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities","volume":"78","author":"Herlitz","year":"2010","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.ajt.2025.09.012_bib21","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1365-2036.2012.05093.x","article-title":"Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B","volume":"35","author":"Gara","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.ajt.2025.09.012_bib22","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/lt.20874","article-title":"Bone mineral density before and after OLT: long-term follow-up and predictive factors","volume":"12","author":"Guichelaar","year":"2006","journal-title":"Liver Transpl"},{"issue":"10","key":"10.1016\/j.ajt.2025.09.012_bib23","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajt.2025.09.012_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2021.100535","article-title":"From Child-Pugh to MELD score and beyond: taking a walk down memory lane","volume":"27","author":"Ruf","year":"2022","journal-title":"Ann Hepatol"},{"issue":"6","key":"10.1016\/j.ajt.2025.09.012_bib25","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ajt.2025.09.012_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.ajt.2025.09.012_bib27","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ajt.2025.09.012_bib28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ajt.2025.09.012_bib29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","article-title":"Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety","volume":"119","author":"Chan","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"11-12","key":"10.1016\/j.ajt.2025.09.012_bib30","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/apt.18278","article-title":"Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: final results from two randomised phase 3 trials","volume":"60","author":"Buti","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.ajt.2025.09.012_bib31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"Lampertico","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.ajt.2025.09.012_bib32","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S2468-1253(24)00096-7","article-title":"Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study","volume":"9","author":"Janssen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.ajt.2025.09.012_bib33","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cgh.2019.05.057","article-title":"Potential benefits of switching liver transplant recipients to tenofovir alafenamide prophylaxis","volume":"18","author":"Sripongpun","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajt.2025.09.012_bib34","doi-asserted-by":"crossref","DOI":"10.12659\/AOT.938731","article-title":"Converting from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with hepatitis B following liver transplantation","volume":"28","author":"Cheng","year":"2023","journal-title":"Ann Transpl"},{"issue":"2","key":"10.1016\/j.ajt.2025.09.012_bib35","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.cgh.2022.01.035","article-title":"Renal outcomes with tenofovir alafenamide in liver transplant recipients","volume":"21","author":"Liu","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.ajt.2025.09.012_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13522","article-title":"Safety and efficacy of tenofovir alafenamide in liver transplant recipients: a single center experience","volume":"23","author":"Rashidi-Alavijeh","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"10.1016\/j.ajt.2025.09.012_bib37","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s12072-022-10320-z","article-title":"Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study","volume":"16","author":"Lee","year":"2022","journal-title":"Hepatol Int"},{"issue":"12","key":"10.1016\/j.ajt.2025.09.012_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13740","article-title":"Long-term outcomes with oral therapy in liver transplant recipients with hepatitis B","volume":"33","author":"Saab","year":"2019","journal-title":"Clin Transpl"},{"issue":"1","key":"10.1016\/j.ajt.2025.09.012_bib39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajt.2025.09.012_bib40","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40620-020-00932-9","article-title":"Comparison of 51Cr-EDTA and 99mTc-DTPA for glomerular filtration rate measurement","volume":"34","author":"Vidal-Petiot","year":"2021","journal-title":"J Nephrol"},{"issue":"5","key":"10.1016\/j.ajt.2025.09.012_bib41","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.ekir.2021.03.879","article-title":"Beyond the glomerulus\u2014kidney tubule markers and diabetic kidney disease progression","volume":"6","author":"Bullen","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ajt.2025.09.012_bib42","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1479-5876-11-201","article-title":"The clinical utility of bone marker measurements in osteoporosis","volume":"11","author":"Wheater","year":"2013","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.ajt.2025.09.012_bib43","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/jhep.2001.21554","article-title":"A multicenter United States\u2014Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B","volume":"33","author":"Perrillo","year":"2001","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ajt.2025.09.012_bib44","doi-asserted-by":"crossref","first-page":"150","DOI":"10.14218\/JCTH.2020.00003","article-title":"Prevention of HBV recurrence after liver transplant: a review","volume":"8","author":"Nasir","year":"2020","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ajt.2025.09.012_bib45","author":"Janssen","year":"2021"},{"issue":"3","key":"10.1016\/j.ajt.2025.09.012_bib46","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4174\/astr.2020.99.3.180","article-title":"Tenofovir does not induce renal dysfunction compared to entecavir in post-liver-transplant hepatitis B virus patients","volume":"99","author":"Kim","year":"2020","journal-title":"Ann Surg Treat Res"},{"issue":"7","key":"10.1016\/j.ajt.2025.09.012_bib47","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3851\/IMP1874","article-title":"Bone turnover, OPG\/RANKL, and inflammation with antiretroviral initiation: comparison of tenofovir- vs. non-tenofovir regimens","volume":"16","author":"Brown","year":"2011","journal-title":"Antivir Ther"},{"issue":"5","key":"10.1016\/j.ajt.2025.09.012_bib48","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/lt.21682","article-title":"Acute kidney injury following liver transplantation: definition and outcome","volume":"15","author":"Barri","year":"2009","journal-title":"Liver Transpl"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613525029892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613525029892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:35:08Z","timestamp":1778621708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613525029892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1600613525029892"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2025.09.012","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of tenofovir alafenamide in preventing hepatitis B virus recurrence after liver transplantation in patients with chronic kidney disease maintained on tenofovir disoproxil fumarate: Results from a phase 2 randomized trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2025.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of American Society of Transplantation & American Society of Transplant Surgeons.","name":"copyright","label":"Copyright"}]}}